Overview

At Tempo Bioscience, we strongly believe in the advantages of using human iPSC-derived cell models for drug discovery (early to late stages), preclinical safety and efficacy assessments, and biomarker authentications. These cell models serve as "nonclinical trials" to evaluate promising drug candidates. For the conference, we will present some of our latest iPSC-derived cell models for the liver 3D/organoids, kidney 3D/spheroids, and the blood-brain-barrier.

Introduction

At Tempo Bioscience, we strongly believe in the advantages of using human iPSC-derived cell models for drug discovery (early to late stages), preclinical safety and efficacy assessments, and biomarker authentications. These cell models serve as "nonclinical trials" to evaluate promising drug candidates. For the conference, we will present some of our latest iPSC-derived cell models for the liver 3D/organoids, kidney 3D/spheroids, and the blood-brain-barrier.

Methods

At Tempo Bioscience, we strongly believe in the advantages of using human iPSC-derived cell models for drug discovery (early to late stages), preclinical safety and efficacy assessments, and biomarker authentications. These cell models serve as "nonclinical trials" to evaluate promising drug candidates. For the conference, we will present some of our latest iPSC-derived cell models for the liver 3D/organoids, kidney 3D/spheroids, and the blood-brain-barrier.

Results

At Tempo Bioscience, we strongly believe in the advantages of using human iPSC-derived cell models for drug discovery (early to late stages), preclinical safety and efficacy assessments, and biomarker authentications. These cell models serve as "nonclinical trials" to evaluate promising drug candidates. For the conference, we will present some of our latest iPSC-derived cell models for the liver 3D/organoids, kidney 3D/spheroids, and the blood-brain-barrier.

Conclusion

At Tempo Bioscience, we strongly believe in the advantages of using human iPSC-derived cell models for drug discovery (early to late stages), preclinical safety and efficacy assessments, and biomarker authentications. These cell models serve as "nonclinical trials" to evaluate promising drug candidates. For the conference, we will present some of our latest iPSC-derived cell models for the liver 3D/organoids, kidney 3D/spheroids, and the blood-brain-barrier.